leisure time -WSS

leisure time

author：hotspot 2025-09-29 01:08:34 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： JPM pitch from hospitals? Revenue streams outside of patient care

leisure time

WSS

Profiling embryos to choose those with higher IQs is almost a reality

The painfully weak evidence on taking collagen to treat arthritis

More regulation could be coming for drug ads

Sage's campaign to raise awareness of postpartum depression hits a nerve

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

leisure time

leisure time

Gilead needs Arcellx more than ever

focus

Affirmative action in medical school literally saved lives

More regulation could be coming for drug ads

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA early review: GLP

FDA approval of Sarepta Duchenne genetic therapy gives me hope

An Ebola outbreak presents a new mystery involving children

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

hotspot

Fauci's latest grilling in Congress: 9 hours, behind closed doors

‘The Bear’ and hospitality in hospitals

Zapping the brain for stroke rehab: Pivotal clinical trial begins

A preacher's new calling: Diversifying neuroscience research

Choosing scientific sides in the fight against Alzheimer's

Merck to acquire Harpoon Therapeutics for $680 million

leisure time

focus

leisure time

Wikipedia